Sensex
74,573.78 profit arw -664.21 (-0.88%)
Nifty
23,381.90 profit arw -261.60 (-1.11%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 18-May-2026
Corporate News
18-May-2026     09:12

Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Injection in U.S.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. Glenmark's Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC.

According to IQVIA' sales data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market2 achieved annual sales of approximately $37.9 million.

INDIAN INDICES

Sensex

74,573.78 -664.21 (-0.88%)

Nifty

23,381.90 -261.60 (-1.11%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,962.74 -426.31(-1.62%)